Showing 1 - 7 results of 7 for search 'Jennifer Dumoulin', query time: 0.03s Refine Results
  1. 1
    Interest of Absolute Eosinopenia as a Marker of Influenza in Outpatients during the Fall-Winter Seasons 2016–2018 in the Greater Paris Area: The SUPERFLUOUS Study

    Interest of Absolute Eosinopenia as a Marker of Influenza in Outpatients during the Fall-Winter Seasons 2016–2018 in the Greater Paris Area: The SUPERFLUOUS Study by Benjamin Davido, Benoit Lemarie, Elyanne Gault, Jennifer Dumoulin, Emma D’anglejan, Sebastien Beaune, Pierre De Truchis

    Published 2023-06-01
    Get full text
    Article
  2. 2
    Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.

    Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. by Coraline Dumenil, Marie-Ange Massiani, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Etienne Giroux Leprieur

    Published 2018-01-01
    Get full text
    Article
  3. 3
    Superinfection is associated with short-term outcome and mortality in viral respiratory tract infections during the fall-winter seasons 2016-2018 in the Greater Paris area: the SUPERFLUOUS study

    Superinfection is associated with short-term outcome and mortality in viral respiratory tract infections during the fall-winter seasons 2016-2018 in the Greater Paris area: the SUP... by Benjamin Davido, Benoit Lemarie, Elyanne Gault, Marion Pepin, Karim Jaffal, Sebastien Beaune, Lotfi Dahmane, Jennifer Dumoulin, Segolene Greffe, Djillali Annane, Pierre De Truchis

    Published 2022-06-01
    Get full text
    Article
  4. 4
    Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer

    Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer by Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Dumenil, Catherine Julie, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie Tisserand, Jean-François Emile, Hélène Blons, Thierry Chinet

    Published 2018-05-01
    Get full text
    Article
  5. 5
    Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

    Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab by Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur

    Published 2018-08-01
    Get full text
    Article
  6. 6
    Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression

    Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression by Jean-François Emile, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Catherine Julie, Thierry Chinet, Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, Paul Takam Kamga, Adrien Costantini, Alexandre Corjon, Simon Garinet

    Published 2020-05-01
    Get full text
    Article
  7. 7
    Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

    Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer by Assya Akli, Paul Takam Kamga, Catherine Julie, Claude Capron, Adrien Costantini, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Florence Parent, Andrei Seferian, Catherine Guettier, Mathieu Glorion, Elisabeth Longchampt, Jean-François Emile, Étienne Giroux-Leprieur

    Published 2025-01-01
    Get full text
    Article

Search Tools: